BioInvent's excellence in science and exceptional range of collaborations form the foundations on which we are building our success.
Our in house capabilities in antibody drug development span discovery through to manufacturing, while our proprietary library of fully-human antibodies, n-CoDeR enables us to choose drug candidates with a high selectivity and affinity for targets. We are also capable of combining target and drug discovery using our F.I.R.S.T™ approach, which includes high throughput functional screening. This is further underpinned with our expertise in characterising the biological properties of antibodies and validating their potential use as therapeutics. In addition to the preclinical and clinical development of antibody therapeutics, we operate an antibody manufacturing facility on site. Both our in house and partnered programmes have benefited from our extensive experience of developing antibody producing cell lines and manufacturing antibodies under cGMP for clinical development studies and commercial products.
As BioInvent is a research-orientated organisation, good science is instrumental to our success. Our studies are currently focused on the area of cancer. Our ongoing research activities involve looking at tumour cells, blood vessel development, macrophages and stroma biology. In all of our research activities we prioritise understanding a drug's mode of action.